Schedule 13D ownership disclosure

Spyre Therapeutics Inc

Security class unavailable · CUSIP: 00773J202

Event date: 2024-04-23

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
Unavailable
Percent of class
9.9900%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-24-114056
Form type
SC 13D/A
Filer
Fairmount Funds Management LLC
CIK
CIK 1802528
Filed
Apr 25, 2024
Reporting period
Apr 23, 2024
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub